This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Encompass Health (EHC) Soars 11.0%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Encompass Health (EHC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Encompass Health (EHC) Opens JV Hospital for Oklahoma Patients
by Zacks Equity Research
Encompass Health (EHC) inaugurated the Owasso-based Ascension St. John Rehabilitation Hospital, that it will operate jointly with Ascension St. John to offer rehabilitative care in Oklahoma.
Encompass Health's (EHC) 155th Hospital Opens in Wisconsin
by Zacks Equity Research
The Rehabilitation Hospital of Western Wisconsin is Encompass Health's (EHC) first location in the state.
Encompass Health (EHC) Down 9.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Encompass Health (EHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Universal Health (UHS) Q4 Earnings Beat on Solid Segments
by Zacks Equity Research
Universal Health's (UHS) fourth-quarter results indicate growing revenues in its segments resulting from higher patient volumes. Management expects adjusted EPS within $9.50-$10.50 for 2023.
Encompass Health's (EHC) Shares Up 3% on Q4 Earnings Beat
by Zacks Equity Research
Encompass Health's (EHC) fourth-quarter results reflect growing patient volumes and reimbursement rates. Management expects 2023 adjusted EPS within $2.87-$3.16, higher than $2.85 in 2022.
Encompass Health (EHC) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Encompass Health (EHC) delivered earnings and revenue surprises of 3.53% and 1.45%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Is ALPS O'Shares U.S. Small-Cap Quality Dividend ETF (OUSM) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for OUSM
Eli Lilly (LLY) Q4 Earnings Surpass Estimates
by Zacks Equity Research
Lilly (LLY) delivered earnings and revenue surprises of 14.21% and 0.28%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Should ALPS O'Shares U.S. Small-Cap Quality Dividend ETF (OUSM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for OUSM
Encompass Health's (EHC) Plan Marks Entry in Rhode Island
by Zacks Equity Research
Encompass Health (EHC) aims to build a 50-bed inpatient rehabilitation hospital in Rhode Island and extend its advanced rehabilitative services suite across the Northeast.
Acadia Healthcare (ACHC) Up 42% in a Year: More Room to Run?
by Zacks Equity Research
Acadia Healthcare (ACHC) is well-poised for growth on a diversified healthcare treatment network resulting from growth-related efforts.
Encompass Health (EHC) Proposes 50-Bed Hospital in Florida
by Zacks Equity Research
Encompass Health (EHC) intends to build a 50-bed inpatient rehabilitation hospital in the Daytona Beach area to further amplify its presence in Florida.
Why Is Encompass Health (EHC) Up 7.5% Despite Q3 Earnings Miss?
by Zacks Equity Research
Encompass Health (EHC) intends to open 6-10 de novo locations and increase the bed count by 100-150 per annum, till 2026.
Encompass Health (EHC) Q3 Earnings Miss Estimates
by Zacks Equity Research
Encompass Health (EHC) delivered earnings and revenue surprises of -1.47% and 2.72%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Addus HomeCare (ADUS) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Addus HomeCare (ADUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Encompass Health (EHC) Q3 Earnings Expected to Decline
by Zacks Equity Research
Encompass Health (EHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Encompass Health (EHC), Piedmont Tie Up to Better Serve Georgia
by Zacks Equity Research
Encompass Health (EHC) collaborates with Piedmont to construct a 40-bed inpatient rehabilitation hospital in Georgia to serve the healthcare needs of the Georgian communities more effectively.
Encompass Health (EHC) Plans Hospital to Aid Florida Footprint
by Zacks Equity Research
Encompass Health (EHC) unveils plans to fortify its U.S. presence via building a 50-bed inpatient rehabilitation hospital in The Villages, Florida.
Encompass Health (EHC) Opens New 50-Bed Hospital in Naples
by Zacks Equity Research
With the new facility in Naples, Encompass Health (EHC) now has 153 inpatient rehabilitation units in total.
Encompass Health (EHC) Down 4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Encompass Health (EHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Encompass Health's (EHC) Future Hospital to Serve Pennsylvania
by Zacks Equity Research
Encompass Health (EHC) decides to develop a 50-bed inpatient rehabilitation hospital in Pennsylvania to better serve the rehabilitative needs of the local communities.
Encompass (EHC) Opens Its 4th Inpatient Rehab Unit in Illinois
by Zacks Equity Research
Encompass Health's (EHC) Quad Cities Rehabilitation Institute has 40 beds and serves patients who are recovering from enervating and complex illnesses and injuries.
Encompass Health (EHC) Up 4.7% Despite Q2 Earnings Miss
by Zacks Equity Research
Encompass Health (EHC) intends to open three additional de novo locations and increase the bed count by 20 in existing facilities this year.
Encompass Health (EHC) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Encompass Health (EHC) delivered earnings and revenue surprises of -8.25% and 1.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?